|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3650 AUD | 0.00% |
|
+4.29% | -43.85% |
| 21/07 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| 20/07 | Recce Pharmaceuticals Extends Share Purchase Plan Closing Date | MT |
| Market Cap | 109M 76.27M 66.93M 62.33M 57.33M 107M 7.29B 739M 289M 3.61B 286M 280M 12.48B | P/E 2026 * |
-5.98x | P/E 2027 * | -4.29x |
|---|---|---|---|---|---|
| Enterprise Value | 115M 79.92M 70.14M 65.31M 60.07M 113M 7.64B 775M 303M 3.79B 300M 294M 13.08B | EV / Sales 2026 * |
14.7x | EV / Sales 2027 * | 10.7x |
| Free-Float |
60.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 week | +4.29% | ||
| Current month | -9.88% | ||
| 1 month | -13.10% | ||
| 3 months | -30.48% | ||
| 6 months | -39.17% | ||
| Current year | -43.85% |
| 1 week | 0.35 |  | 0.38 |
| 1 month | 0.35 | | 0.41 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.76 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/2/26 | Expiration | Chief Executive Officer | 2,250,000 | 0.7781% | ||
| 14/10/25 | Expiration | Chief Executive Officer | 745,962 | 0.3217% | ||
| 21/11/24 | Buy | Director | 1,000,000 | 0.4313% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +4.29% | -6.41% | -48.95% | 76.27M | |
| +0.16% | +4.48% | +59.26% | +167.32% | 1,089B | |
| +0.25% | +4.50% | +58.91% | +59.46% | 643B | |
| +1.17% | +4.86% | +38.91% | +77.58% | 465B | |
| -1.05% | +9.51% | +40.27% | +34.52% | 359B | |
| -0.74% | +3.53% | +36.99% | +42.48% | 303B | |
| +1.48% | +3.23% | +17.51% | +17.22% | 267B | |
| +0.51% | +5.38% | -2.94% | -38.34% | 226B | |
| +0.16% | +7.65% | +29.81% | +68.29% | 212B | |
| -0.58% | +2.06% | +16.45% | +74.70% | 167B | |
| Average | +0.17% | +4.43% | +28.88% | +45.43% | 373.12B | |
| Weighted average by Cap. | +0.24% | +5.14% | +42.68% | +81.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.78M 5.43M 4.76M 4.44M 4.08M 7.65M 519M 52.62M 20.6M 257M 20.38M 19.94M 889M | 12.5M 8.72M 7.65M 7.13M 6.55M 12.28M 833M 84.53M 33.09M 413M 32.73M 32.02M 1.43B |
| Net income | -18.29M -12.76M -11.2M -10.43M -9.59M -17.98M -1.22B -124M -48.44M -605M -47.92M -46.88M -2.09B | -25.1M -17.51M -15.37M -14.31M -13.16M -24.68M -1.67B -170M -66.46M -830M -65.74M -64.32M -2.87B |
| Net Debt | 5.24M 3.65M 3.21M 2.99M 2.75M 5.15M 349M 35.41M 13.86M 173M 13.71M 13.42M 598M | 24.96M 17.42M 15.29M 14.23M 13.09M 24.54M 1.66B 169M 66.1M 825M 65.39M 63.98M 2.85B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/07/26 | $0.3650 | 0.00% | 35,714 |
| 28/07/26 | $0.3650 | -2.67% | 34,989 |
| 27/07/26 | $0.3750 | +4.17% | 134,821 |
| 24/07/26 | $0.3600 | 0.00% | 65,425 |
| 23/07/26 | $0.3600 | +2.86% | 213,680 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
